Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
“At a time of transitioning our CFO position, BJ’s Restaurants required an experienced public company Interim CFO to shepherd the company’s finance function. During this period, William Atkins of FLG Partners was a key member of our senior leadership team and partnered with his operating and financial colleagues at BJ’s to ensure the performance of our quarterly and year-end financial reporting and business planning functions. Our Board and executive team were impressed by William’s adaptability, discipline, and focus. We highly recommend FLG for assignments that require experienced, hands-on leadership and are grateful for the firm’s involvement at an important time in BJ’s development.”
James A. Dal Pozzo, Director and C. Bradford Richmond, Director, BJs Restaurants, Inc. Read More
